Provides for the treatment of patients with advanced or metastatic breast cancer whose tumors over-express HER2 (ErbB2) and who have received prior therapy including and anthracycline, a taxane and trastuzumab.

N021817

Reclast

zoledronic acid

Novartis

3

P

16-Apr-2007

Provides for the treatment of Paget's disease of bone.

N022088

Torisel

temsirolimus

Wyeth

1

P,O

30-May-2007

Provides for the treatment of advanced renal cell carcinoma.

N022116

Lexiva

fosamprenavir calcium

GlaxoSmithKline

3

P

14-Jun-2007

Provides for the treatment of HIV infection.

N022081

Letairis

ambrisentan

Gilead Sciences

1

P,O

15-Jun-2007

Provides for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening.

N022128

Selzentry

maraviroc

Pfizer

1

P

06-Aug-2007

Provides for the treatment of patients infected with CCR5-tropic HIV-1.

N022025

Totect

dexrazoxane

Alba BioPharm

5

P

06-Sep-2007

Provides for the treatment of extravasation resulting from IV anthracycline chemotherapy.

N020981

Hycamtin

topotecan

GlaxoSmithKline

3

P

11-Oct-2007

Provides for the treatment of relapsed small cell lung cancer in patients with prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.

N022145

Isentress

raltegravir pottassium

Merck

1

P

12-Oct-2007

Provides in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

N022065

Ixempra

ixabepilone

Bristol-Myers Squibb

1

P

16-Oct-2007

Provides in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.
The new drug also provides as monotherapy for the treatment of matastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

N022048

Triesence

triamcinolone acetonide

Alcon

3

P

29-Nov-2007

Provides for the treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteriods. Also, is indicated for visualization during vitrectomy.

N022181

Kuvan

sapropterin dihydrochloride

BioMarin

1

P,O

13-Dec-2007

Provides for the reduction of blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU).